Amarin Corporation plc (ADR) Stock Xetra
Equities
EH3A
US0231112063
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
||
0.783 EUR | 0.00% |
Sales 2024 * | 202M 187M 277M | Sales 2025 * | 215M 199M 295M | Capitalization | 358M 331M 492M |
---|---|---|---|---|---|
Net income 2024 * | -70M -64.74M -96.08M | Net income 2025 * | -64M -59.19M -87.85M | EV / Sales 2024 * | 1.55 x |
Net cash position 2024 * | 43.92M 40.62M 60.28M | Net cash position 2025 * | 159M 147M 218M | EV / Sales 2025 * | 0.93 x |
P/E ratio 2024 * |
-4.94
x | P/E ratio 2025 * |
-5.24
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.48% |
Latest transcript on Amarin Corporation plc (ADR)
Managers | Title | Age | Since |
---|---|---|---|
Patrick Holt
CEO | Chief Executive Officer | 52 | 23-07-17 |
Thomas Reilly
DFI | Director of Finance/CFO | 52 | 22-06-19 |
Compliance Officer | 55 | 11-14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Louis Sterling
BRD | Director/Board Member | 45 | 23-02-27 |
Odysseas Kostas
CHM | Chairman | 49 | 23-02-27 |
Keith Horn
BRD | Director/Board Member | 66 | 23-02-27 |
1st Jan change | Capi. | |
---|---|---|
+10.79% | 115B | |
+11.65% | 106B | |
-6.20% | 24.69B | |
-2.33% | 21.97B | |
-6.03% | 19.27B | |
-13.41% | 17.56B | |
-40.50% | 17.32B | |
+6.64% | 14.03B | |
+31.84% | 12.13B |
- Stock Market
- Equities
- AMRN Stock
- EH3A Stock